AGEN AGENUS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1098972 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY25.4%
TTM net income YoY187.7%
TTM EPS YoY114.6%
Revenue 3-yr CAGR9.9%
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin38.9%
Net margin23.0%
FCF margin-77.5%
EBITDA margin40.6%
Returns
ROE—
ROA12.9%
ROIC (approx.)—
Asset turnover0.56x
Leverage & solvency
Liabilities / assets145.7%
Debt / equity—
Current ratio0.73x
Interest coverage0.85x
Cash quality & payout
Operating cash flow / net income-3.37x
Accruals ratio56.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $114.20M | $103.46M |
| Cost of revenue | $1.02M | $486,000 |
| Gross profit | $113.17M | $102.98M |
| R&D expense | $79.34M | $155.53M |
| SG&A expense | $54.39M | $71.88M |
| Operating income | -$20.17M | -$120.47M |
| Interest expense | $55.62M | $120.42M |
| Pretax income | -$3.08M | -$232.27M |
| Income tax | $0 | $0 |
| Net income | $115,000 | -$227.21M |
| EBITDA | -$10.17M | -$107.13M |
| EPS (basic) | 0.00 | -10.59 |
| EPS (diluted) | 0.00 | -10.59 |
| Weighted avg. shares (diluted) | 29.73M | 21.47M |
| Balance sheet | ||
| Cash & equivalents | $3.00M | $40.44M |
| Short-term investments | $0 | — |
| Receivables | $1.83M | $407,000 |
| Current assets | $133.44M | $45.57M |
| PP&E, net | $15.47M | $120.09M |
| Goodwill | $24.09M | $24.09M |
| Intangibles | $3.04M | $3.38M |
| Total assets | $226.80M | $226.27M |
| Current liabilities | $323.49M | $221.40M |
| Short-term debt | $44.66M | $2.70M |
| Long-term debt | $0 | $30.47M |
| Total debt | $44.66M | $33.17M |
| Total liabilities | $504.66M | $532.70M |
| Shareholders' equity | -$271.11M | -$326.38M |
| Net debt | $41.66M | -$7.27M |
| Shares outstanding | 35.32M | 23.63M |
| Cash flow statement | ||
| Operating cash flow | -$77.19M | -$158.31M |
| Capital expenditure | $6,000 | $576,000 |
| Free cash flow | -$77.20M | -$158.89M |
| Investing cash flow | $1.19M | $27,000 |
| Financing cash flow | $36.59M | $122.84M |
| Depreciation & amortization | $10.00M | $13.34M |
| Stock-based compensation | $13.77M | $17.39M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.